Recombinant Proteins iso9001 ISO13485
搜索
 > 【B7-H4】重组蛋白信息

B7-H4信息

英文名称:V-set domain-containing T-cell activation inhibitor 1
中文名称:含V区域T细胞激活抑制因子1
靶点别称:V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,
上市药物数量:0
临床药物数量:1
最高研发阶段:临床一期

B7-H4产品列表

 
评论(1)
B74-H82E2|Biotinylated Human B7-H4 Protein, Avitag™,His Tag (recommended for biopanning)
  1. 150XXXXXXX1
  2. 2人赞
  3. 总共购买了600ug的这款biotin的抗原,用于液相panning和亲和力成熟的screening。这个抗原稳定性很好,质量过关,每次试验的可重复性高。 用这个抗原筛到了高亲和力的针对这靶点的抗体。并且用这个抗原做亲和力成熟的筛选,也获得了亲和力提高10倍的抗体。推荐购买哦~~
  4. 2019-10-11
 

B7-H4 分子别名

B7-H4,VTCN1,B7S1,B7h.5

B7-H4 分子背景

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

B7-H4 参考文献

B7-H4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
FPA-150 FPA-150 临床一期 Five Prime Therapeutics 卵巢癌, 移行细胞癌, 膀胱癌, 乳腺癌, 子宫内膜样癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定